Skip to main content
Condition

Depression: When Medication Isn’t Enough

If antidepressants haven’t resolved your depression, the problem may not be the medication. It may be what the medication was never designed to fix—neuroinflammation, mitochondrial failure, and metabolic deficiencies that prevent your brain from producing and regulating the neurochemistry it needs.

Schedule a ConsultationCall (912) 268-3097

Depression Is Not a Serotonin Shortage

The serotonin hypothesis dominated psychiatric thinking for decades, but the clinical evidence has moved beyond it. Moncrieff et al. (2022, Molecular Psychiatry) published a comprehensive umbrella review concluding that the evidence does not support a direct link between serotonin levels and depression. This does not mean SSRIs are useless—they help some patients through mechanisms we are still clarifying. It means that serotonin deficiency is not the whole story, and for many patients, it is not the story at all.

A more compelling explanation has emerged from neuroimmunology. Raison et al. (2006, Archives of General Psychiatry) demonstrated that pro-inflammatory cytokines—particularly interleukin-6, TNF-alpha, and C-reactive protein—are consistently elevated in patients with major depression. These inflammatory molecules cross the blood-brain barrier and directly interfere with neurotransmitter synthesis, synaptic plasticity, and neurogenesis in the hippocampus.

Miller and Raison (2016, Nature Reviews Immunology) further established that chronic low-grade inflammation activates the kynurenine pathway, diverting tryptophan away from serotonin production and toward quinolinic acid—a neurotoxic metabolite that damages hippocampal neurons and impairs glutamatergic signaling. This is not a subtle biochemical footnote. It is a mechanism that explains why patients with elevated inflammatory markers respond poorly to SSRIs: the medication targets a downstream receptor while the upstream metabolic pathway is being hijacked.

For these patients, the question is not which antidepressant to try next. The question is what is driving the inflammation, and what metabolic conditions are preventing the brain from functioning normally even when medication is present.

The Metabolic Roots of Treatment Resistance

A patient with depleted folate cannot methylate properly. Without adequate methylation, the synthesis of serotonin, dopamine, and norepinephrine is impaired at the enzymatic level. No SSRI corrects a folate deficiency. Coppen and Bolander-Gouaille (2005, Journal of Psychopharmacology) demonstrated that low serum folate predicts poor antidepressant response and that methylfolate augmentation improves outcomes in patients who have failed standard therapy.

Vitamin B12 deficiency produces a parallel disruption. B12 is a required cofactor in the methionine synthase reaction that regenerates methionine from homocysteine—the same pathway that supplies methyl groups for neurotransmitter synthesis. Patients with B12 levels in the low-normal range often have functional deficiency that standard lab ranges miss. Elevated methylmalonic acid and homocysteine reveal what serum B12 alone does not.

Vitamin D deficiency is independently associated with depression. Anglin et al. (2013, British Journal of Psychiatry) conducted a meta-analysis of over 31,000 participants and found a significant association between low vitamin D and depression. Vitamin D receptors are distributed throughout the hippocampus, prefrontal cortex, and hypothalamus—regions central to mood regulation.

Thyroid dysfunction, even subclinical hypothyroidism, produces depressive symptoms that are indistinguishable from major depression on clinical assessment. Free T3—the biologically active thyroid hormone—and reverse T3 levels are frequently abnormal in treatment-resistant patients whose TSH falls within the reference range. These are correctable conditions. They are also conditions that most patients with depression have never had properly evaluated.

Our Diagnostic Approach

Every depression evaluation at The Neurogenesis Project begins with the premise that treatment resistance has a cause, and that cause is identifiable. Dr. Orr conducts a comprehensive neurological examination and orders targeted laboratory panels designed to surface the specific metabolic, inflammatory, and mitochondrial factors sustaining your depressive symptoms.

Lab work evaluates inflammatory biomarkers including high-sensitivity CRP, interleukin-6, and TNF-alpha. Metabolic panels measure folate, methylfolate, vitamin B12, methylmalonic acid, homocysteine, 25-hydroxyvitamin D, a complete thyroid panel with free T3 and reverse T3, fasting insulin, and hemoglobin A1c. Mitochondrial function markers and oxidative stress indicators identify the bioenergetic deficits that sustain neuronal underperformance.

When clinically indicated, advanced neuroimaging evaluates regional brain metabolism and structural integrity. Brain PET imaging can reveal hypometabolism in frontal and temporal regions that correlates with depressive symptom severity. These findings guide treatment decisions with a level of precision that symptom-based prescribing cannot achieve.

Dr. Drew Edwards evaluates each patient’s cognitive and behavioral profile through the NeuroCoaching framework, identifying functional deficits in motivation, executive function, and emotional regulation that inform the behavioral component of the treatment plan.

How We Treat This

Each treatment targets a specific mechanism contributing to treatment-resistant depression. Protocols are built from individual diagnostic findings, not applied as a standard regimen.

NAD+ IV Therapy

Restores the coenzyme required for mitochondrial ATP production in neurons. Addresses the bioenergetic deficit that impairs neurotransmitter synthesis, synaptic maintenance, and neuroplasticity in depressed patients.

Glutathione IV Therapy

The brain’s primary antioxidant. Intravenous glutathione reduces oxidative stress that damages neuronal membranes and mitochondria, directly addressing the oxidative burden elevated in treatment-resistant depression.

Metabolic Optimization

Targeted correction of folate, B12, vitamin D, thyroid, and other metabolic deficiencies identified on lab work. Restores the biochemical substrate that neurotransmitter synthesis depends on.

NeuroCoaching

Dr. Edwards’ behavioral optimization framework translates neurological and metabolic findings into actionable strategies for motivation, executive function, and daily structure during recovery.

Myers’ Cocktail IV

Delivers magnesium, B-complex vitamins, and vitamin C intravenously, bypassing gastrointestinal absorption limitations. Supports enzymatic pathways critical to neurotransmitter production and cellular energy metabolism.

Advanced Neuroimaging

Brain MRI and PET imaging evaluate structural integrity and regional metabolic activity. Identifies patterns of frontal hypometabolism and hippocampal changes associated with chronic depression.

Related Treatments

Anxiety: A Neurological Perspective

Anxiety and depression share overlapping inflammatory and metabolic pathways. Many patients carry both diagnoses, and treating the underlying neurology addresses the common root rather than managing each symptom set separately.

Brain Health Lab Panels

The comprehensive metabolic and inflammatory panels that form the diagnostic foundation of our depression evaluation. Identifies the specific deficiencies and imbalances driving your symptoms.

Long COVID & Brain Fog

Post-COVID neuroinflammation frequently manifests as depression, cognitive impairment, and fatigue. The inflammatory mechanisms overlap significantly with treatment-resistant depression pathways.

Frequently Asked Questions

How is a neurological evaluation for depression different from what my psychiatrist does?+
Psychiatry evaluates symptoms and prescribes medications that modulate neurotransmitter activity at the synapse. A neurological evaluation looks upstream. We measure the metabolic, inflammatory, and mitochondrial conditions that determine whether your neurons can produce and regulate neurotransmitters in the first place. If your folate is depleted, your methylation cycle cannot synthesize serotonin precursors regardless of which SSRI you take. If chronic neuroinflammation is suppressing BDNF production, synaptic plasticity is impaired at a level medication does not reach. We identify these root causes with lab work, metabolic panels, and neuroimaging, then treat them directly. This is not a replacement for psychiatric care. It is the layer underneath it that most patients have never had evaluated.
What lab tests do you run for treatment-resistant depression?+
Our workup includes inflammatory biomarkers such as high-sensitivity C-reactive protein, interleukin-6, and TNF-alpha. We evaluate metabolic contributors including serum folate, methylfolate, vitamin B12, methylmalonic acid, homocysteine, 25-hydroxyvitamin D, thyroid panel with free T3 and reverse T3, fasting insulin, hemoglobin A1c, and a comprehensive metabolic panel. Mitochondrial function markers, oxidative stress indicators, and cortisol patterns are assessed. When clinically indicated, we order advanced neuroimaging to evaluate regional brain metabolism and structural integrity. The goal is to identify every correctable factor contributing to your depressive symptoms.
How does NAD+ therapy help with depression?+
NAD+ is the central coenzyme in mitochondrial energy production. Depressed patients frequently show mitochondrial dysfunction — neurons that cannot produce adequate ATP to support normal synaptic transmission, neurotransmitter synthesis, and neuroplasticity. Intravenous NAD+ restores cellular energy metabolism directly. It also serves as a required substrate for sirtuins, which regulate inflammatory gene expression and DNA repair. By replenishing NAD+ levels, we address the bioenergetic deficit that underlies many cases of treatment-resistant depression rather than attempting to redistribute neurotransmitters that are not being adequately produced.
Will I need to stop my current medications to receive treatment?+
No. Our protocols are designed to work alongside existing psychiatric medications, not replace them. NAD+ IV therapy, glutathione, and metabolic optimization do not interact with SSRIs, SNRIs, or other standard antidepressants. We coordinate with your prescribing psychiatrist or physician throughout the process. Many patients find that once the underlying metabolic and inflammatory contributors are corrected, they are able to work with their prescriber to adjust medications — but that decision is always made collaboratively with the provider managing your psychiatric care.
How long before I notice improvement?+
Patients receiving our Intensive Brain Health Program typically complete treatment over three to five consecutive days. Many report improvements in energy, cognitive clarity, and sleep quality within the first one to two weeks. The inflammatory and metabolic corrections we initiate take longer to produce their full effect — most patients describe meaningful, sustained improvement in mood and function over four to eight weeks. Follow-up infusion cycles may be recommended at intervals based on your clinical response and repeat lab findings. Depression that has persisted for years did not develop overnight, and durable recovery requires addressing the underlying biology systematically.
Does insurance cover neurological treatment for depression?+
The Neurogenesis Project operates outside of insurance networks. Our diagnostic and treatment protocols use therapies not typically covered by commercial insurance or Medicare. We provide detailed superbills and medical documentation that patients can submit to their carriers for potential out-of-network reimbursement. Our patient coordinator can discuss costs, payment plans, and documentation options before you schedule.

Depression Has a Neurology. We Evaluate It.

If your depression has not responded to medication, the answer is not always a different medication. It may be that the metabolic, inflammatory, and mitochondrial conditions driving your symptoms have never been identified or treated. Dr. Orr and Dr. Edwards at The Neurogenesis Project are accepting new patients in St. Marys, Georgia.

Schedule Your Evaluation(912) 268-3097